Table 3.
Comparison of the incidence of coagulopathy in patients with COVID-19 and SARS.
| Authors | Severity | N | SIC | DIC |
|---|---|---|---|---|
| COVID-19 | ||||
| Tang et al. [6] | NA | 183 | NA | 71.4% of non-survivors met ISHT-DIC criteria; only 1 (0.6%) survivor met DIC criteria 4 days after admission |
| Helms et al. [10] | All in ICU | 150 | Only 22 patients (14.7%) had a positive SIC score | Only 6 patients (2.7%) had a positive JAAM score, 144 patients (96%) had a normal JAAM-DIC score. All patients had a normal ISTH-DIC score |
| Fogarty et al. [13] | 23 in ICU | 83 | NA | None met DIC criteria at the time of admission |
| Tang et al. [15] | All had severe COVID-19 | 449 | 21.6% had a SIC score ≥ 4. Heparin treatment was associated with lower mortality in patients with a SIC score ≥ 4, but not in those with a SIC score < 4 | NA |
| Lodigiani et al. [36] | 48 in ICU | 388 | NA | 2.1% of patients met overt DIC criteria, no bleeding complications occurred |
| SARS | ||||
| Wong et al. [37] | NA | 157 | NA | 2.5% of patients developed overt DIC |
COVID-19: Coronavirus disease 2019; DIC: Disseminated intravascular coagulation; ICU: Intensive care unit; ISHT: International Society on Thrombosis and Haemostasis; JAAM: Japanese Association for Acute Medicine; SARS: Severe acute respiratory syndrome; SIC: Sepsis-induced coagulopathy; NA: Not available.